Intelligence Platform
Patents
Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 8664219
Aminopyrimidines useful as inhibitors of protein kinases
granted patentUS 8664251
Ryanodine receptor inhibitors for treatment of T-cell mediated disorders
granted patentUS 8658669
Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
granted patentUS 8653070
Hepatitis C virus inhibitors
granted patentUS 8653088
Compositions useful as inhibitors of protein kinases
granted patentUS 8648037
Macrocyclic proline derived HCV serine protease inhibitors
granted patentUS 8642779
Compositions useful as inhibitors of protein kinases
granted patentUS 8642751
MicroRNA inhibitors comprising locked nucleotides
granted patentUS 8642282
Inhibitors of nitric oxide synthase for treatment of melanoma
granted patentUS 8637675
Inhibitors of proliferation and activation of signal transducer and activators of transcri
granted patentUS 8637666
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
granted patentUS 8637568
Serotonin reuptake inhibitors
granted patentUS 8637511
Aminopyrimidines useful as kinase inhibitors
granted patentUS 8633210
Triazole compounds useful as protein kinase inhibitors
granted patentUS 8633205
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases
granted patentUS 8629156
Tryptophan hydroxylase inhibitors
granted patentUS 8623869
Compounds useful as inhibitors of ATR kinase
granted patentUS 8623867
Cyclic amine BACE-1 inhibitors having a benzamide substituent
granted patentUS 8618331
Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
granted patentUS 8618290
HSP90 inhibitors
granted patentUS 8618152
Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
granted patentUS 8618106
Protein kinase inhibitors
granted patentUS 8618090
Inhibitors of the plasmodial surface anion channel as antimalarials
granted patentUS 8609848
Pyrazolone-derivatives and their use as PDE-4 inhibitors
granted